These initial results in our EOC efficacy-evaluable population are in line with Phase 2 results of other PARP inhibitors, which have been approved for use in patients with platinum-sensitive ovarian cancer [3, 15, 16]. The gene discussed is PARP1; the disease is ovarian cancer.